Education
Medical Degree: obtained at University of Rome la “Sapienza” with maximum mark, 16 October 1986.
Medical license: no. 38245, obtained on 23 March 1987.
Board Certified in Hematology: University of Rome “Tor Vergata” with maximum mark, 24 July 1989.
1990 “Research Fellow” (National Council Research grant), Dept. Immunology, Royal Free Hospital, London (UK).
1990-91 “Visiting Fellow” Dept. Haematology and Cytogenetics, Royal Marsden Hospital, London (UK).
Quality assurance system auditor for the healthcare sector:July 2007- present.
Master F.A.M.E.(Future Advance in Management Expertise): obtained at SDA Bocconi – School of Management, Jan-March 2012. Management training program for onco-hematologists consisting in 3 in units:
Unit 1: management of “Unità Operative Complesse”.;
Unit 2: diagnostic-therapeutic procedures;
Unit 3: communication skills;
Academic Appointments and Professional Experiences
Full Professor of Hematology: 2021-present.
Associate Professor of Hematology:Dept. Hematology University "Tor Vergata" of Rome, 2001 - 2021.
Director of the Transplant Unit (U.O.C): at Azienda Ospedaliera Universitaria Policlinico Tor Vegata, 2021 – present.
Director of the Hematology Unit (U.O.S.D.):at Azienda Ospedaliera Universitaria Policlinico Tor Vegata, 2018 – present.
Director of the Hematology Unit (U.O.C.):at Azienda Ospedaliera Universitaria Policlinico Tor Vegata, 2016 – 2018.
Coordinator of the “Diagnostic-therapeutic work-up”unitfor Acute Myeloid Leukemia” at Hematology, Fondazione Policlinico Tor Vergata, 2016 – present.
Medical Manager and Head of the research program “Advanced Therapy in Hematology”:at Azienda Ospedaliera Universitaria Policlinico Tor Vegata, 2008 - 2018.
Medical Manager:at Azienda Ospedaliera Universitaria Policlinico Tor Vegata, 2005 – 2008.
Head of the Laboratory for Diagnosis in Hematology:Hematology, Ospedale S.Eugenio, 2003 – 2005.
Assistant Member:Dept. Hematology University "Tor Vergata" of Rome, 1989 – 2001.
Involvement in Research Teams and/or National/International Societies
-
General Secretary of the Italian Society of Hematology Board, 2003 - 2009.
-
Member of the “Acute leukemia Working Party” of “Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA)”, 2009 - present.
-
Elected Member of the Italian Society of Hematology Board, 2010- 2017.
-
Member of the Committee for Educational Activities of the Italian Society of Hematology, 2010 - 2021.
-
Coordinator of the "Writing Committee" of the Italian Society of Hematology for the development of Guidelines for the diagnosis and treatment of Acute Myeloid Leukemia in younger patients, 2023 – present.
-
Coordinator of the "Writing Committee" of the Italian Society of Hematology for the development of Guidelines for the diagnosis and treatment of Acute Myeloid Leukemia in older patients, 2014 – present.
-
Member of the “Acute Leukemia Working Party” of the ’European Organization for Research and Treatment of Cancer (EORTC), 2007 – present.
-
Member of the "European LeukemiaNet Work package on minimal residual disease", 2007 - present.
-
Member of the “European LeukemiaNet writing committee” for the development of recommendations on the use of minimal residual disease in acute myeloid leukemia, (manuscript published in Blood, in 2018, update published in 2021), 2015 - present.
-
Chairman of the “Acute leukemia Working Party” of “Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA)”, 2021 - present.
-
Chairman of the Leukemia Group of European Organization for Research and Treatment of Cancer (EORTC), 2023-present.
-
Member of the “Data Safety Monitoring Board” (DSMB) of the European Organization for Research and Treatment of Cancer (EORTC), 2017 – present.
-
Coordinator of the " European LeukemiaNet Writing Committee" for the development of recommendations for the definition of unfitness in Acute Myeloid Leukemia, 2019 – present.
-
Member of the “Harmony Core Group” established to develop the project entitled “Measurable residual disease as surrogate marker for survival in AML: an individual patient-level correlation”, 2021-present.
-
Member of the “Steering Committee of Siremadlin study” (Novartis), 2021-2023.
-
Member of the “Steering Committee of VIALE-M study” (Abbvie), 2022-2023.
-
Member of the “Steering Committee of ALIDHE study” (Servier), 2022-present.
-
Member of the “Myeloid Steering Committee” (Abbvie), 2023-present.
PUBLICATIONS
Two hundred and 70 manuscripts published in peer-reviewed journals.
ID ORCID: 0000-0002-0245-0553
ID SCOPUS: 7005726094 and 57827623100
ID RESEARCHER: E-4139-2015
h-index: 49 (Scopus); 47(Web of Science); 54 (ResearchGate); 60 (Google Scholar)
a:0:{}"
}
["meta_keywords"]=>
array(1) {
[0]=>
string(56) "Chemioterapia,Ematologia,drugs,chemotherapy,haematology,"
}
["reserved"]=>
array(1) {
[0]=>
string(1) "0"
}
["auth_ip"]=>
array(1) {
[0]=>
string(1) "0"
}
}
["_fieldBoosts":protected]=>
array(6) {
["content_id"]=>
bool(false)
["content_title"]=>
bool(false)
["description"]=>
bool(false)
["meta_keywords"]=>
bool(false)
["reserved"]=>
bool(false)
["auth_ip"]=>
bool(false)
}
}
}